Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

HUMANA INC (HUM)

As of 2026-11-18 · 12/15 boxes filled from SEC filings and market data

Report price $385.78 (close 2026-11-18); latest close $390.00 (2026-11-20), +1.1% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -39% · upside +19%

At $385.78 the market pays 30.9x adjusted TTM earnings and 2.46x book for a 6.6% return on common equity, above the company's own 23.1x five-year median and above every profitable large peer. What is being priced is a margin recovery that management itself pushes into FY2026, with adjusted EPS guided to at least $9.50 against $17.14 in FY2025 on the Bonus Year 2026 Star Ratings headwind. PASS: the asymmetry does not pay. The downside is -38.2% to $238.30, on -25.0% earnings at a compressed P/E of 25.45x (today 30.9x). The upside is +20.0% to $462.94, on +20% earnings at today's P/E of 30.9x. That is a reward/risk of 0.52. There is no base case: no comparable peer multiple sets one, because the peers' P/E is GAAP and the company's GAAP P/E of 37.2x is more than 5% from the adjusted 30.9x the downside sits on, so a base at the peer multiple would rest on other earnings than either case. Conviction is low.

Key numbers

  • Share price: $390.00
  • Market cap: $46.84B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $154.19B
  • P/E (TTM): 37.6x
  • Price / book: 2.49x
  • Earnings-quality flags (TTM): Impairments -$253.0M (20% of net income)
  • P/E, adjusted (TTM): 31.2x
  • Revenue growth (latest fiscal year): +10.1%

The 15 boxes

  1. ✓ 1. Long-form business notes

    Humana is a government-payment health insurer: FY2025 premiums and services revenue of $129.66B (up from $77.16B in FY2020), 83% of it from federal contracts, with 96.3% of FY2025 premiums and services revenue ($123,842M) sitting in the Insurance segment and individual Medicare Advantage alone at $90,403M (70.3%). Membership has shifted and shrunk in count (15.0M medical members at 12/31/2025 versus ~17M at 12/31/2020) while individual MA grew to 5,249.3K from 3,962.7K, keeping Florida at roughly 14% of consolidated revenue. Earnings went the other way: operating income fell from $4.99B (FY2020) to $2.70B (FY2025) and $2.38B (TTM to 9/30/2026) on nearly double the revenue, with FY2025 net income $1.19B. As an insurer it is valued on earnings, book equity ($17.66B at 12/31/2025) and capital return, not enterprise value or EBITDA.

  2. ✓ 2. Competitive advantage

    The sources describe no durable advantage: Humana competes in a highly competitive health benefits industry against other managed care companies, national insurers and HMOs/PPOs, many with larger membership and greater financial resources in its markets, and the 10-K states barriers to entry are not substantial and customers can switch plans relatively easily each Medicare Annual Enrollment Period. The financial record is consistent with weak pricing power: revenue rose from $77.16B (FY2020) to $129.66B (FY2025) and $154.19B (TTM to 2026-09-30) while operating income fell from $4.99B to $2.70B and $2.38B, and net income from $3.37B to $1.19B and $1.25B, over the same periods. The main quality lever, Medicare Advantage Star Ratings, deteriorated, and the models are shaped by CMS and state policy rather than by a moat.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 was a revenue-growth, margin-pressure quarter: total revenues rose 26.1% to $41.2 billion on Medicare membership growth, but the consolidated benefit ratio rose 280 bp to 93.9% and consolidated income from operations fell 81.3% to $75 million. GAAP EPS of $1.33 was flattered by a $358 million non-cash put/call valuation gain, leaving an Adjusted loss per share of $0.70 versus Adjusted EPS of $3.24 in Q3 2025. Management raised FY 2026 Adjusted EPS guidance to 'at least $9.50' from 'at least $9.00' and revised GAAP EPS guidance to 'at least $15.09' from 'at least $6.52'. Cash built to about $6.9 billion from $4.2 billion at December 31, 2025 on $5.4 billion of nine-month operating cash flow, helped by the $908 million MaxHealth acquisition and the new BlackRock primary-care joint venture.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans